Clinical trials: Menopause
Osteoporosis in Post-menopausal Women
Safety and Efficacy of Whole-body Vibration as add-on Treatment of Osteoporosis in Post-menopausal Women
Multicentered, randomized study of safety and efficacy of whole-body vibration (WBV) as add on to standard pharmacological treatment of osteoporosis (alendronate 70 mg/ week or raloxifene 60 mg/day) in post-menopausal women.
- Trial name
- NCT01415050
- Testing
- Whole body vibration
- Where
- 5 sites in Germany
- Volunteers
- 80 people
- Sponsor
- X-pert Med GmbH
Post Menopausal Osteoporosis
ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study.
- Trial name
- NCT00545090
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 17 sites in Hong Kong, Indonesia and 3 more
- Volunteers
- 561 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
This study is a post-authorisation study, committed to Center for Drug Evaluation (CDE) and China Food and Drug Administration (CFDA), in order to provide more effectiveness and safety data about Faslodex in real world clinical…
- Trial name
- NCT01425294
- Where
- 23 sites in China
- Volunteers
- 231 people
- Sponsor
- AstraZeneca
Menopause Syndrome
Evaluation of the Efficacy and Safety of A High Molecular Weight, Natural Hyaluronic Acid Vaginal Gel in Women With Genitourinary Syndrome of Menopause
The aim of the study is to evaluate the safety and efficacy of the vaginal gel with HMW HA in women with genitourinary syndromes due to either menopause or other causes such as the patients after ovarian or breast cancer…
- Trial name
- NCT05263102
- Testing
- Vaginal Moisturizing Gel
- Where
- 4 sites in Taiwan
- Volunteers
- 80 people
- Sponsor
- HAN Biomedical Inc
Post-menopausal Vasomotor Symptoms
Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts.
- Trial name
- RELENT-1 (NCT02865538)
- Testing
- BAY3427080
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Bayer
Menopause, Postmenopausal Vaginal Atrophy
Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms
This trial is conducted in North America. The purpose of this study is to determine if Vagifem Low Dose is an effective and safe treatment for patients suffering from postmenopausal atrophic vaginitis.
- Trial name
- NCT00108849
- Testing
- estradiol, 10 mcg
- Where
- 57 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Novo Nordisk A/S
Biological Availability
Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam
Quantify the effect of a probe CYP3A4 inducer (Rifampicin) on the pharmacokinetics of levonorgestrel, norethindrone, desogestrel, dienogest, drospirenone,estradiol and midazolam
- Trial name
- NCT03353857
- Testing
- levonorgestrel/ Microlut, Norethindrone/ Noriday, Desogestrel/ Cerazette
- Where
- 2 sites in Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Bayer
Menopause
A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.
- Trial name
- REPLENISH (NCT01942668)
- Testing
- Estradiol, Progesterone
- Where
- 119 sites in United States
- Volunteers
- 1,845 people
- Sponsor
- TherapeuticsMD
Perimenopausal Disorder, Menopause
Inovium Ovarian Rejuvenation Trials
The Inovium Ovarian Rejuvenation Treatment is a PRP-based autologous treatment used in combination with a stimulated IVF sequence and Pre-Implantation Genetic Screening to treat infertility in women experiencing menopause…
- Conditions
- Perimenopausal Disorder, Menopause, Menopause, Premature, Menopause Related Conditions
- Trial name
- NCT03178695
- Testing
- Autologous PRP injection into human ovarian tissue
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ascendance Biomedical
Sexual Dysfunction, Physiological
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
CP-866,087 is a non-hormonal compound, acting on the central nervous system, which has been shown in animal models to restore sexual function.
- Trial name
- NCT00482664
- Testing
- CP-866,087
- Where
- 12 sites in Australia, Denmark and 3 more
- Volunteers
- 84 people
- Sponsor
- Pfizer
Osteoporosis
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
This is an 18-month, double-blind, placebo-controlled, Phase III trial with a 12-month interim analysis of the effect of ALX1-11, recombinant human parathyroid hormone (1-84) (rhPTH [1-84]), on fracture incidence in women with…
- Trial name
- NCT00172081
- Testing
- ALX1-11
- Where
- 174 sites in United States, Argentina and 7 more
- Volunteers
- 2,532 people
- Sponsor
- Shire
Osteoporosis
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of 3 doses of ALX1-11 (recombinant human parathyroid hormone [rhPTH(1-84)])(50, 75 and 100 µg) in the treatment of postmenopausal…
- Trial name
- NCT00172107
- Testing
- ALX1-11 50 mcg, ALX1-11 75mcg, ALX1-11
- Where
- 19 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- Shire
Vasomotor Symptoms, Menopausal Symptoms
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)
A two-part study designed to evaluate the effect of Estetrol (E4) 15 mg, 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) in the Efficacy Study Part and the safety of E4 20 mg in the Safety Study Part.
- Trial name
- E4Comfort II (NCT04090957)
- Testing
- Estetrol oral tablet
- Where
- 117 sites in United States, Canada
- Volunteers
- 1,015 people, healthy volunteers welcome
- Sponsor
- Estetra
Menopause Hot Flashes
MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
The purpose of this study is to assess the efficacy and safety of MT-8554 for treatment of vasomotor symptoms (VMS) associated with menopause.
- Trial name
- NCT03291067
- Testing
- MT-8554 1mg, MT-8554 5mg, MT-8554 10mg
- Where
- 63 sites in United States
- Volunteers
- 375 people
- Sponsor
- Tanabe Pharma America, Inc.
Menopause
Open-labelled Study to Evaluate the Effect of SE5-OH Tablets on Healthy Women With Menopausal Symptoms
Multicentre, exploratory, prospective, open-labelled study to evaluate the efficacy of SE5-OH tablets on menopausal symptoms in healthy women experiencing menopausal symptoms after 12 weeks of administration.
- Trial name
- NCT06398236
- Testing
- SE5-OH tablets
- Where
- Spain
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Nutrition & Sante Iberia
Endometrial Cancer
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
- Trial name
- NCT01251354
- Testing
- BN83495
- Where
- 9 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Ipsen
Pre-menopausal Breast Cancer, PI3K Pathway Inhibition
A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
Based on the evidence acquired in the post-menopausal setting with everolimus and on pre-clinical evidences supporting the investigation of PI3K inhibitors, such as alpelisib and buparlisib, in combination with endocrine therapy…
- Trial name
- B-YOND (NCT02058381)
- Testing
- alpelisib (BYL719), buparlisib (BKM120)
- Where
- 15 sites in Hong Kong, South Korea and 2 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Vasomotor Symptoms Associated With Menopause
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective in the treatment of moderate to severe vasomotor symptoms associated with menopause.
- Trial name
- NCT00234819
- Testing
- Bazedoxifene/Conjugated Estrogen
- Where
- 7 sites in United States
- Volunteers
- 325 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopausal Osteoporosis
BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
This 2 arm study will assess the impact of Bone Marker Feedback (BMF), using blood sampling and communication of the results at 2 months, on adherence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis.
- Trial name
- NCT00545909
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 57 sites in Austria, Belgium and 3 more
- Volunteers
- 585 people
- Sponsor
- Hoffmann-La Roche
Menopause, Bone Demineralization
A Study to Learn More About the Menopausal Hormone Therapies in Korea
The purpose of this study is to learn about how the commonly used menopausal hormone therapies were prescribed and taken in practice.
- Trial name
- NCT06033521
- Testing
- Menopausal hormone therapy Intervention Type: Drug
- Where
- South Korea
- Volunteers
- 1,036,294 people
- Sponsor
- Pfizer